Altimmune(ALT) - 2024 Q2 - Quarterly Results

Exhibit 99.1 Altimmune Announces Second Quarter 2024 Financial Results and Provides a Business Update Recent presentations at major medical meetings provide further support for the differentiated profile of pemvidutide in obesity and metabolic dysfunction-associated steatohepatitis (MASH) Enrollment progressing in Phase 2b IMPACT trial of pemvidutide in MASH with topline data expected in Q1 2025 Cash, cash equivalents and short-term investments of $164.9 million on June 30, 2024 Webcast to be held today, Au ...